The overexpression of FTO in leukemia cells can promote its expression by catalyzing the demethylation of cell proliferation-related genes such as m6A of MERTL and BCL-2 mRNA and affecting the generation of resistance phenotypes in the treatment with tyrosine kinase inhibitors (TKI) (Yan et al., 2018). Here, FTO is linked to leukemia.